About TwinStrand Biosciences
TwinStrand Biosciences is a private company based in Seattle, Washington. It has reported $84,977,112 raised in six offerings on Form D since June 2016.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 20, 2023 | Jun 30, 2023 | $10,278,497of $25.7M target | 9 | $1.1M | EquityRule 506(b) | Form D ↗ |
| Apr 30, 2021 | May 12, 2021 | $49,999,943fully sold | 21 | $2.3M | EquityRule 506(b) | Form D ↗ |
| Dec 16, 2019 | Dec 30, 2019 | $16,301,834fully sold | 45 | $362K | EquityRule 506(b) | Form D ↗ |
| Aug 15, 2018 | Aug 27, 2018 | $1,177,536of $4.0M target | 23 | $51,197 | DebtRule 506(b) | Form D ↗ |
| Aug 30, 2017 | Sep 13, 2017 | $5,280,338of $5.5M target | 39 | $135K | EquityRule 506(b) | Form D ↗ |
| Jun 10, 2016 | Jun 24, 2016 | $1,938,964of $2.2M target | 18 | $107K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, six offerings | $84,977,112 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on TwinStrand Biosciences's Form D filed Jun 30, 2023.
Earlier filings also listed Steve Dow (director, last listed May 2021), Kellie Bickel (executive officer, last listed May 2021), Jesse Salk (chief executive officer and director, last listed May 2021), Elena Cant (executive officer, last listed May 2021), Terry Myerson (director, last listed Dec 2019), Michele Fernandes (executive officer, last listed Dec 2019), Lawrence Loeb (director and promoter, last listed Aug 2018) and Christopher Benoit (chief executive officer and director, last listed Aug 2018).